PubRank

Eric Tartour

Author PubWeight™ 85.95‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008 4.30
2 Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002 3.17
3 Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006 2.56
4 PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2012 2.43
5 Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 2011 2.16
6 Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med 2013 2.15
7 Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012 1.88
8 Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012 1.78
9 VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 2012 1.67
10 IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res 2011 1.59
11 Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012 1.51
12 A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 2011 1.51
13 Gene polymorphisms and cytokine plasma levels as predictive factors of complications after cardiopulmonary bypass. J Thorac Cardiovasc Surg 2012 1.47
14 A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol 2008 1.47
15 A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010 1.40
16 Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2012 1.34
17 Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012 1.33
18 Immune infiltration in human cancer: prognostic significance and disease control. Curr Top Microbiol Immunol 2011 1.32
19 Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology 2013 1.31
20 Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012 1.30
21 A Fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines. J Immunol Methods 2003 1.29
22 Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 2003 1.27
23 Trial watch: Cardiac glycosides and cancer therapy. Oncoimmunology 2013 1.21
24 Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2012 1.19
25 Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res 2008 1.18
26 Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology 2012 1.18
27 Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012 1.17
28 Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). Int J Cancer 2004 1.17
29 Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res 2012 1.16
30 Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology 2012 1.09
31 Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013 1.09
32 A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother 2010 1.08
33 Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol 2012 1.01
34 Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head Neck 2010 1.00
35 The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur J Immunol 2006 0.97
36 Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother 2008 0.96
37 Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res 2012 0.96
38 The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. Cancer Res 2008 0.96
39 B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity. J Immunol 2007 0.95
40 Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013 0.95
41 Revisiting the prognostic value of regulatory T cells in patients with cancer. J Clin Oncol 2009 0.90
42 HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers. Cancer Immun 2010 0.90
43 The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization. Int Immunol 2003 0.89
44 1st class ticket to class I: protein toxins as pathfinders for antigen presentation. Traffic 2002 0.89
45 Comprehensive analysis of HLA-DR- and HLA-DP4-restricted CD4+ T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients. J Immunol 2008 0.89
46 Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo. Blood 2010 0.89
47 Characterization of immune functions in TRAF4-deficient mice. Immunology 2008 0.87
48 Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor. Clin Cancer Res 2012 0.87
49 The angiogenic growth factor and biomarker midkine is a tumor-shared antigen. J Immunol 2010 0.87
50 Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate. Melanoma Res 2008 0.86
51 [PD-1 and PDL-1 expression in cancer: significance and prognostic value]. Med Sci (Paris) 2013 0.84
52 Dendritic cell-induced apoptosis of human cytomegalovirus-infected fibroblasts promotes cross-presentation of pp65 to CD8+ T cells. J Gen Virol 2008 0.83
53 Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses. Clin Cancer Res 2006 0.82
54 NK cells from pleural effusions are potent antitumor effector cells. Eur J Immunol 2013 0.82
55 Efficacy of DNA vaccines forming e7 recombinant retroviral virus-like particles for the treatment of human papillomavirus-induced cancers. Hum Gene Ther 2013 0.82
56 [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy]. Bull Cancer 2003 0.81
57 Early impairment of CD8+ T cells immune response against Epstein-Barr virus (EBV) antigens associated with high level of circulating mononuclear EBV DNA load in HIV infection. J Clin Immunol 2004 0.81
58 [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab]. Bull Cancer 2010 0.81
59 Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents. Expert Rev Anticancer Ther 2014 0.81
60 Following up tumor-specific regulatory T cells in cancer patients. Oncoimmunology 2013 0.80
61 Inhibition of the differentiation of monocyte-derived dendritic cells by human gingival fibroblasts. PLoS One 2013 0.80
62 Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subset. Vaccine 2011 0.79
63 Fluorospot assay: methodological analysis. Methods Mol Biol 2005 0.79
64 Optimization of an elispot assay to detect cytomegalovirus-specific CD8+ T lymphocytes. Hum Immunol 2004 0.79
65 Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites. Hum Vaccin Immunother 2014 0.79
66 Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+ T cells. BMC Cancer 2013 0.79
67 VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer. Oncoimmunology 2013 0.78
68 Arginine administration to critically ill patients with a low nitric oxide fraction in the airways: a pilot study. Intensive Care Med 2013 0.78
69 Correlation between Shiga toxin B-subunit stability and antigen crosspresentation: a mutational analysis. FEBS Lett 2007 0.78
70 The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Front Immunol 2011 0.78
71 Immunotherapy of HPV-associated head and neck cancer: Critical parameters. Oncoimmunology 2013 0.77
72 An unusual human papillomavirus type 82 detection in laryngeal squamous cell carcinoma: case report and review of literature. J Clin Virol 2012 0.76
73 Correspondence to Creydt VP et al., Cytotoxic effect of Shiga toxin-2 holotoxin and its B subunit on human renal tubular epithelial cells, Microbes Infect. 8(2) (2006) 410-419. Microbes Infect 2006 0.75
74 A suicide gene therapy combining the improvement of cyclophosphamide tumor cytotoxicity and the development of an anti-tumor immune response. Curr Gene Ther 2014 0.75
75 [Phenotypic and functional analysis of T lymphocytes in cancer patients]. Ann Pathol 2005 0.75
76 Smoking and the Association Between Depressive Symptoms and Absolute Neutrophil Count in the Investigations Préventives et Cliniques Cohort Study. Psychosom Med 2015 0.75